Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
Recruiting · NCT03827876 · Interventional (participants receive a specific treatment) · Lead sponsor: Psoriasis Treatment Center of Central New Jersey
View the official record on ClinicalTrials.gov →Interventions studied
Enstilar 0.005%-0.064% Topical Foam
What this trial is about
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10% BSA who are receiving etanercept or adalimumab for at least 24 weeks
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 4
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Patient with 2-10% BSA
- Physician Global Assessment of 2 or greater
- Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion criteria
- ˂2 or \>10% BSA
- PGA \<2
- Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab \<24weeks
Where it is running
1 location listed across 1 US state.
- Psoriasis Treatment Center of Central New Jersey - East Windsor, New Jersey, United States